ARQ Wealth Advisors LLC Raises Holdings in Medtronic PLC $MDT

ARQ Wealth Advisors LLC grew its stake in shares of Medtronic PLC (NYSE:MDT) by 478.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,983 shares of the medical technology company’s stock after buying an additional 22,316 shares during the period. ARQ Wealth Advisors LLC’s holdings in Medtronic were worth $2,338,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Medtronic by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after acquiring an additional 1,888,381 shares during the last quarter. State Street Corp grew its position in Medtronic by 2.0% during the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after acquiring an additional 1,199,621 shares during the period. JPMorgan Chase & Co. increased its stake in Medtronic by 2.7% during the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after acquiring an additional 1,419,730 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after purchasing an additional 3,880,174 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Medtronic by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock worth $2,665,832,000 after purchasing an additional 231,919 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Stock Up 1.7%

Medtronic stock traded up $1.39 during midday trading on Friday, hitting $83.78. 7,190,992 shares of the stock were exchanged, compared to its average volume of 8,643,010. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm has a market cap of $107.24 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.25 and a beta of 0.56. The company has a 50 day moving average price of $79.11 and a two-hundred day moving average price of $88.53.

Medtronic (NYSE:MDT) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same period last year, the firm earned $1.62 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, June 26th. This represents a $2.88 annualized dividend and a yield of 3.4%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is presently 77.21%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MDT shares. Citigroup dropped their target price on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. UBS Group decreased their price objective on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. TD Cowen dropped their price objective on shares of Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. BTIG Research upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Wednesday, June 3rd. Finally, Weiss Ratings cut shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.17.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen cut its price target on Medtronic to $100 from $119 but kept a buy rating, signaling the stock still has meaningful upside from current levels. TD Cowen lowers price target on Medtronic
• Positive Sentiment: Another recent bullish note said Medtronic’s guidance is conservative and “built to be beaten,” highlighting strong fiscal 2026 revenue growth and potential upside catalysts from the MiniMed separation, tariff refunds, and payment relief. Medtronic guidance built to be beaten
• Positive Sentiment: Another Seeking Alpha article argued Medtronic is undervalued and that tailwinds are just beginning, reinforcing the idea that investors may be underappreciating the company’s growth potential. Medtronic undervalued and tailwinds just getting started
• Positive Sentiment: Citi also reportedly initiated or reiterated a buy view on Medtronic, adding to the wave of favorable analyst sentiment. Medtronic receives a buy from Citi
• Neutral Sentiment: Medtronic disclosed a voluntary global recall of its Octopus 4 Tissue Stabilizer after an assembly issue affecting 590 units. The issue appears limited, but recalls can create short-term investor caution. Medtronic recalls Octopus 4 Tissue Stabilizer
• Neutral Sentiment: Separate valuation pieces on Medtronic suggest the stock remains cheap relative to fundamentals, but these are more interpretation than hard catalysts for the share price. Medtronic stock could be undervalued

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).